{"id":"W4385217389","doi":"10.1158/1535-7163.mct-23-0065","title":"First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pharmacyclics; EMD Serono; Adaptive Biotechnologies; GlaxoSmithKline; Exelixis; Genentech; AstraZeneca; Taiho Pharmaceutical; Pfizer","keywords":"Medicine; Internal medicine; Nausea; Adverse effect; Anemia; Gastroenterology; Mucositis; Neutropenia; Combination therapy; Refractory (planetary science); Pharmacokinetics; Olaparib; Cancer; Diarrhea; Toxicity; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002186453,0.001873359,0.003062841,0.000512676,0.0005676329,0.001345619,0.0009926145,0.001294485,0.003216457],"category_scores_gemma":[0.001045665,0.0009160654,0.002162112,0.000477577,0.001158581,0.001230321,0.0004867435,0.003970495,0.001134348],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001352786,"about_ca_system_score_gemma":0.00158245,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009270687,"about_ca_topic_score_gemma":0.003331152,"domain_scores_codex":[0.9992892,0.000333444,0.00003667179,0.0001080854,0.00005959093,0.0001730446],"domain_scores_gemma":[0.9990759,0.000164686,0.0001519074,0.0001172766,0.00005820864,0.0004320261],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5017945,0.1902601,0.01485873,0.001332234,0.003367058,0.001171629,0.0006424022,0.003236453,0.07697292,0.0004705032,0.00754478,0.1983488],"study_design_scores_gemma":[0.2627344,0.7106238,0.0122839,0.0000408013,0.0008863067,0.0004800551,0.00009195207,0.0009594102,0.00642789,0.0002042797,0.00522107,0.00004614618],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983132,0.00684153,0.001048445,0.0005451331,0.0001900518,0.002895832,0.002130643,0.000173894,0.003042426],"genre_scores_gemma":[0.9842202,0.004418667,0.001523585,0.001354951,0.0003346404,0.00172036,0.002977199,0.00006289445,0.003387467],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003216457,"threshold_uncertainty_score":0.01156318,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0121741033571396,"score_gpt":0.249141873966883,"score_spread":0.2369677706097434,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}